1986
Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.
Winkler C, Sausville E, Ihde D, Fischmann A, Schechter G, Kumar P, Nibhanupdi J, Minna J, Makuch R, Eddy J. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up. Journal Of Clinical Oncology 1986, 4: 1094-100. PMID: 3088220, DOI: 10.1200/jco.1986.4.7.1094.Peer-Reviewed Original ResearchConceptsTotal skin electron beam irradiationStage I patientsCutaneous T-cell lymphomaDisease-free survivalT-cell lymphomaI patientsStage IIComplete responseModality treatmentCell lymphomaStage IMedian disease-free survivalDisease-free survivorsThree-drug regimensCombined modality treatmentAdvanced-stage patientsOverall response rateOral corticosteroidsAdvanced diseaseSystemic chemotherapyProtocol treatmentTopical therapyStage patientsCR rateSimultaneous chemotherapy
1985
Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer.
Johnson B, Becker B, Goff W, Petronas N, Krehbiel M, Makuch R, McKenna G, Glatstein E, Ihde D. Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer. Journal Of Clinical Oncology 1985, 3: 1659-67. PMID: 2999346, DOI: 10.1200/jco.1985.3.12.1659.Peer-Reviewed Original ResearchConceptsProphylactic cranial irradiationMental status examinationLarge radiotherapy fractionsCranial irradiationStatus ExaminationScan abnormalitiesNeuropsychologic testingSmall-cell lung cancer trialHigh-dose induction chemotherapyLow-dose maintenance chemotherapySmall cell lung cancerRadiotherapy fractionsAbnormal neurologic examinationCranial tomography scanProgressive ventricular dilatationTherapeutic cranial irradiationTomography scan abnormalitiesHigh-dose chemotherapyStart of therapyLong-term survivorsLung cancer trialsMajority of casesCCT findingsInduction chemotherapyMaintenance chemotherapyPrognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival
Ihde D, Matthews M, Makuch R, McIntire K, Eddy J, Seeff L. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival. The American Journal Of Medicine 1985, 78: 399-406. PMID: 2579551, DOI: 10.1016/0002-9343(85)90330-4.Peer-Reviewed Original ResearchConceptsAlpha-fetoprotein levelsFibrolamellar carcinomaHepatocellular carcinomaSystemic chemotherapyNormal serum alpha-fetoprotein levelsHepatitis B serum markersNormal alpha-fetoprotein levelsSerum alpha-fetoprotein levelsElevated alpha-fetoprotein levelsAmbulatory performance statusHomogeneous clinical featuresAbsence of cirrhosisHepatitis B markersTime of diagnosisGroup of patientsInitiation of treatmentLack of jaundiceAmbulatory statusExtrahepatic metastasesPerformance statusImproved survivalIndolent coursePrognostic factorsClinical featuresSerum markers
1982
Experience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer.
Minna J, Bunn P, Carney D, Cohen M, Cuttita F, Fosieck B, Gazdar A, Ihde D, Johnston-Early A, Matthews M, Makuch R, Oie H, Rosen S, Lichter A, Glatstein E. Experience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer. Bulletin Du Cancer 1982, 69: 83-93. PMID: 6280795.Peer-Reviewed Original Research
1981
Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy
Von Hoff D, Casper J, Bradley E, Sandbach J, Jones D, Makuch R. Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. The American Journal Of Medicine 1981, 70: 1027-1032. PMID: 7234870, DOI: 10.1016/0002-9343(81)90859-7.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsColony-Forming Units AssayFalse Negative ReactionsFalse Positive ReactionsHumansIn Vitro TechniquesNeoplasmsRetrospective StudiesConceptsIndividual patient's tumorPatient tumorsHuman tumorsGeneral oncology patientsParticular patient's tumorSeparate histologic typesProspective clinical trialsDrug sensitivity assaysColony-forming assaysHistologic typeOncology patientsClinical trialsPatient responsePatientsRetrospective mannerTumorsAntineoplastic agentsFluid specimenEnough cellsVivo resultsSensitivity assaysDrugsAssaysAssociationChemotherapyInfluence of prognostic factors on survival in Ewing's sarcoma.
Glaubiger D, Makuch R, Schwarz J. Influence of prognostic factors on survival in Ewing's sarcoma. National Cancer Institute Monograph 1981, 285-8. PMID: 7300894.Peer-Reviewed Original ResearchConceptsPrimary diseaseEwing's sarcomaTreatment groupsSerum lactate dehydrogenase levelIntensive adjuvant chemotherapySystemic chemotherapy regimensLactate dehydrogenase levelsNumber of patientsSignificant differencesNational Cancer InstituteRecent treatment regimensAdjuvant chemotherapyChemotherapy regimensPrognostic factorsPrimary lesionTreatment regimensLDH levelsMetastatic statusSurvival resultsDehydrogenase levelsTreatment protocolLocal irradiationCancer InstituteSarcomaPrimary site
1980
Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma
Glaubiger D, Makuch R, Schwarz J, Levine A, Johnson R. Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 1980, 45: 2213-2219. PMID: 7370962, DOI: 10.1002/1097-0142(19800415)45:8<2213::aid-cncr2820450834>3.0.co;2-l.Peer-Reviewed Original ResearchConceptsDisease-free survivalPrognostic factorsEwing's sarcomaTreatment groupsLactic acid dehydrogenasePrimary diseaseSerum lactic acid dehydrogenaseSystemic chemotherapy regimensFavorable prognostic factorTime of presentationLactic acid dehydrogenase levelsNumber of patientsResults of treatmentNational Cancer InstituteLatest regimensChemotherapy regimensMetastatic diseaseFavorable prognosisMetastatic statusFavorable outcomeTherapeutic resultsDehydrogenase levelsTreatment protocolLocal irradiationCancer Institute
1979
Serum glycoproteins in head and neck squamous carcinoma Correlations with tumor extent, clinical tumor stage, and T-cell levels during chemotherapy
Wolf G, Chretien P, Elias E, Makuch R, Baskies A, Spiegel H, Weiss J. Serum glycoproteins in head and neck squamous carcinoma Correlations with tumor extent, clinical tumor stage, and T-cell levels during chemotherapy. The American Journal Of Surgery 1979, 138: 489-500. PMID: 90464, DOI: 10.1016/0002-9610(79)90407-0.Peer-Reviewed Original ResearchConceptsΑ1-acid glycoprotein levelsT cell levelsTumor stageAcute phase proteinsUntreated patientsSerum levelsTumor extentCellular immunityImmune reactivitySquamous carcinomaPhase proteinsGlycoprotein levelsSpecific acute phase proteinsCompletion of chemotherapyClinical tumor stageChronic cigarette smokersΑ1-antitrypsin levelsΑ1-antitrypsinCellular immune parametersNeck squamous carcinomaPreoperative chemotherapyRecurrent carcinomaAlbumin levelsControl patientsRegional metastasesRecommendations for the analysis of the effect of treatment on the development of second malignancies
Makuch R, Simon R. Recommendations for the analysis of the effect of treatment on the development of second malignancies. Cancer 1979, 44: 250-253. PMID: 455251, DOI: 10.1002/1097-0142(197907)44:1<250::aid-cncr2820440141>3.0.co;2-1.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsFollow-Up StudiesHumansNeoplasmsNeoplasms, Multiple PrimaryNeoplasms, Radiation-InducedRiskStatistics as TopicThymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer.
Cohen M, Chretien P, Ihde D, Fossieck B, Makuch R, Bunn P, Johnston A, Shackney S, Matthews M, Lipson S, Kenady D, Minna J. Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer. JAMA 1979, 241: 1813-5. PMID: 219267, DOI: 10.1001/jama.241.17.1813.Peer-Reviewed Original ResearchConceptsThymosin fraction VIntensive remission induction chemotherapySmall cell bronchogenic carcinomaSmall cell lung cancerComplete response rateRemission induction chemotherapyWeeks of chemotherapyIntensive combination chemotherapySurvival of patientsRelapse-free survivalThymosin administrationThymosin treatmentComplete respondersCombination chemotherapyBronchogenic carcinomaImmune deficitsLung cancerSurvival durationSurvival timeTreatment groupsResponse rateChemotherapyPatientsFraction VTreatmentCyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.
Cohen M, Ihde D, Bunn P, Fossieck B, Matthews M, Shackney S, Johnston-Early A, Makuch R, Minna J. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Journal Of The National Cancer Institute 1979, 63: 163-70. PMID: 221114.Peer-Reviewed Original ResearchConceptsSmall cell bronchogenic carcinomaResistant drug combinationsCell bronchogenic carcinomaCR rateCombination chemotherapyComplete responseBronchogenic carcinomaDrug combinationsExtensive disease patientsLimited disease patientsProtocol-eligible patientsHigh-dose cyclophosphamideBrain radiation therapyDisease-free survivalComplete respondersDrug regimensProlong survivalInitial treatmentRadiation therapyPatientsVP-16ChemotherapyCarcinomaSequential useMonthscis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.
Young R, Von Hoff D, Gormley P, Makuch R, Cassidy J, Howser D, Bull J. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Journal Of The National Cancer Institute 1979, 63: 1539-44. PMID: 387224.Peer-Reviewed Original ResearchConceptsCombination chemotherapy studiesAdvanced ovarian cancerSingle-agent activityOverall response rateLife-table analysisOvarian Cancer StudyEvaluable patientsForced diuresisSubstantial nauseaHematologic toxicityChemotherapy studiesRenal toxicityOvarian adenocarcinomaOvarian cancerResponse ratePatientsCancer studiesTreatmentToxicityNauseaVomitingDiuresisAdenocarcinomaMajor roleTherapy